TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

factor and other newly approved biologic therapies: case finding through the emerging infections network.
Clin Infect Dis 2008;46:1738-40.
11A.4 Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009;22:
403-9.
11A.5 Wright A et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the
Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73.
11A.6 Devasia RA et al. Fluoroquinolone resistance in Mycobacterium tuberculosis. The effect of duration
and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365-70.
11A.7 Lee E et al. Evolution and current use of the tuberculin test. Clin Infect Dis 2002;34:365-70.
11A.8 American Thoracic Society (ATS) et al. Targeted tuberculin testing and treatment of latent tuberculosis
infection. Am J Respir Crit Care Med 2000;161(4 suppl.):S221-47.
11A.9 Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent
tuberculosis in children and adolescents. Pediatrics 2004;114:1175-201.
11A.10 Cobelens FG et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced
cutoff values. Clin Infect Dis 2006;43:634-9.
11A.11 Tissot F et al. Influence of Bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction:
to what size? Clin Infect Dis 2005;40:211-7.
11A.12 Mandalakas AM et al. Interpretation of repeat tuberculin skin testing in international adoptees. Conversions
or boosting. Pediatr Infect Dis J 2008;27:913-9.
11A.13 Slovis BS et al. The case against anergy testing as a routine adjunct to tuberculin skin testing. J Am
Med Assoc 2000;283:2003-7.
11A.14 Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma
release assays to detect Mycobacterium tuberculosis infection. Morb Mortal Wkly Rep 2010;59(RR-
5):1-25.
11A.15 Mazurek GH et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-γ
release assays in persons with suspected tuberculosis.Clin Infect Dis 2007;45:837-45.
11A.16 Dewan PK et al. Low sensitivity of a whole-blood interferon-γ release assay for detection of active tuberculosis.
Clin Infect Dis 2007;44:69-73.
11A.17 Pai M et al. Interferon-γ release assays: what is their role in the diagnosis of active tuberculosis? Clin
Infect Dis 2007;44:74-7.
11A.18 Al-Zamel FA. Detection and diagnosis of Mycobacterium tuberculosis. Expert Rev Anti Infect Ther
2009;7:1099-108.
11A.19 Lalvani A et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigenspecific
T cells. Am J Respir Crit Care Med 2001;163:824-8.
11A.20 Barnes PF. Diagnosing latent tuberculosis infection. The 100-year upgrade. Am J Respir Crit Care
Med 2001;163:807-8.
11A.21 Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006;
174:736-42.
11A.22 Kim SH et al. Diagnostic usefulness of a T-cell-based assay for extrapulmonary tuberculosis in immunocompromised
patients. Am J Med 2009;122:189-95.
11A.23 Menzies D et al. Meta-analysis. New tests for the diagnosis of latent tuberculosis infection: areas of
uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54.
11A.24 Dosanjh DP et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008;
148:325-36.
11A.25 Bakir M et al. Prognostic value of a T-cell-based, interferon-γ biomarker in children with tuberculosis
contact. Ann Intern Med 2008;149:777-86.
11A.26 Zar HJ et al. Diagnosis of pulmonary tuberculosis in children: new advances. Expert Rev Anti Infect
Ther 2010;8:277-88.
11A.27 Wallis RS et al. Biomarkers and diagnostics for tuberculosis: progress, needs and translation into
practice. Lancet 2010;375:1920-37.
11A.28 Dorman SE et al. New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clin Infect Dis
2010;50(suppl. 3):S173-7.
11A.29 Nyendak MR et al. New diagnostic methods for tuberculosis. Curr Opin Infect Dis 2009;22:174-83.
11A.30 Bergamini BM et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection
in children and adolescents. Pediatrics 2009;123:e419-24.
11A.31 Vlaamse Vereniging voor Respiratoire gezondheidszorg en Tuberculosebestrijding (VRGT). Gerichte
opsporing en behandeling van latente tuberculose-infectie. Available at: http://www.vrgt.be/uploads/
documentenbank/c4d70b10d8a40db8a94189b949f54fd8.pdf. Accessed on August 9 th 2010.
11A.32 Fonds des affections Respiratoires et pour l‘Education à la Santé (FARES). Recommendations
concernant le dépistage ciblé et le traitement de l‘infection tuberculeuse latente. Available at: http://
www.fares.be/documents/recomm.pdf. Accessed on August 9 th 2010.
11A.33 Menzies D et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy
for latent tuberculosis infection a randomized trial. Ann Intern Med 2008;149:689-97.
11A.34 Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis
infection. J Am Med Assoc 2005;293:2776-84.
11A.35 Jasmer RM et al. Latent tuberculosis infection. N Engl J Med 2002;347:1860-6.
11A.36 Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl
J Med 2004;350:2060-7.
11A.37 American Thoracic Society (ATS) et al. Targeted tuberculin testing and treatment of latent tuberculosis
infection. Am J Respir Crit Care Med 2000;161(4 suppl.):S221-47.
11A.38 Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent
tuberculosis infection in children and adolescents. Pediatrics 2004;114:1175-201.
11A.39 Nolan CM et al. Hepatotoxicity associated with isoniazid preventive therapy. A 7-year survey from a
public health tuberculosis clinic. J Am Med Assoc 1999;281:1014-8.
11A.40 McElroy PD et al. National survey to measure rates of liver injury, hospitalization and death associated
with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33.
11A.41 Ijaz K et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide
for latent tuberculosis infection. Clin Infect Dis 2006;42:346-55.
11A.42 van Hest R et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis
treatment. Clin Infect Dis 2004;39:488-96.
11A.43 Gordin FM et al. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection
in HIV infected persons: is it different than in HIV uninfected persons? Clin Infect Dis 2004;
39:561-5.